Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Bamlanivimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade |
|---|---|
| Species | Humanized |
| Expression system | Mammalian cells |
| Molecular weight | 150kDa |
| Purity | >85% |
| Buffer | PBS pH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | 4°C for short term; -20°C for long term |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Bamlanivimab,Bamlanivimab,Covid Spike RBD,anti-Covid Spike RBD |
| Reference | PX-TA1031 |
| Publications |
|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1 |
| Clonality | Monoclonal Antibody |
General information on Anti-SARS-CoV2 Spike RBD (Bamlanivimab) Monoclonal Antibody
Bamlanivimab is a synthetic monoclonal antibody (mAb) that was developped from the first blood samples from COVID-19 recovered patients in the United States. Bamlanivimab is a neutralizing IgG1 mAb targetting the SARS-CoV-2 spike, which prevents the virus from entering human cells. It has been found to recognize first type and variants referenced as PX-COV-P046 and PX-COV-P052.
SDS-PAGE for Bamlanivimab Biosimilar - Anti-Covid Spike RBD mAb
Bamlanivimab Biosimilar - Anti-Covid Spike RBD mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Related products
Antigen
RBD Domain
PX-COV-P046
195€
Isotype Control
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
PTX17885-100
180€
SIL
Stable Istotope Labelled Bamlanivimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade
PX-TA1031-SIL
1500€
Contact us
Got a question or need a quote?
Message us and we’ll get back to you 48 hours or less.
Toshi –
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants (IC50 135.73 ng/mL for the wild type, 185.54 ng/mL for Alpha, >500 ng/mL for Gamma and Delta).
Toshi –
This antibody along with other therapeutic antibodies were tested in surrogate virus neutralization test using spike trimers and ACE2 protein. This antibody showed expected neutralization of wild type, Alpha, Gamma, and Delta variants (IC50 135.73 ng/mL for the wild type, 185.54 ng/mL for Alpha, >500 ng/mL for Gamma and Delta).